-
12/01/2015
PAION announces initiation of U.S. clinical safety trial of Remimazolam in high risk patients undergoing colonoscopy
-
11/11/2015
PAION AG reports results for the first nine months 2015
-
10/27/2015
Launch of new PAION Corporate Website
-
10/14/2015
PAION receives positive feedback from Japanese authority PMDA about production of Remimazolam for Japan
-
10/12/2015
Remimazolam posters at Anesthesiology® 2015
-
08/27/2015
Juergen Raths, MD appointed as Chief Operating Officer at PAION AG
-
08/12/2015
PAION AG reports financial results for the first half-year of 2015
-
08/11/2015
PAION starts EU Phase III study with Remimazolam in the indication general anesthesia
-
08/07/2015
Timothy E. Morris joins PAION, Inc. as a non-executive Director
-
07/23/2015
PAION completed Remimazolam know-how and tech transfer from Ono
-
07/07/2015
Dr. Mariola Söhngen will leave management board of PAION AG as of 31 October 2015 and PAION plans new composition of executive management
-
06/08/2015
PAION announces initiation of second U.S. Phase III clinical trial of Remimazolam for procedural sedation during bronchoscopy
-
05/13/2015
PAION AG reports financial results for the first quarter 2015
-
05/07/2015
David Bernstein, M.D. joins PAION as medical advisor
-
03/31/2015
PAION announces initiation of U.S. Phase III clinical trial of Remimazolam for procedural sedation during colonoscopy
-
03/18/2015
PAION AG reports financial results for the full year 2014